Recent Comments

Comment RSS

Psoriasis News and Research RSS Feed - Psoriasis News and Research

Psoriasis is a chronic, immune-mediated disease that results from the overproduction of skin cells, resulting in their accumulation on the surface of the skin, which causes red, scaly plaques that may itch and bleed. It is estimated that approximately 7.5 million Americans and nearly 3 percent of the world's population are living with psoriasis and nearly one-quarter of those people have cases that are considered moderate to severe.

Ligand Pharmaceuticals' SARM LGD-4033 study data presented at the Gerontology Society of America meeting

20. November 2009 08:37
Ligand Pharmaceuticals Incorporated today announced that data from a preclinical study on its selective androgen receptor modulator (SARM) LGD-4033 was featured in a poster presentation at the 62nd Annual Meeting of the Gerontology Society of America in Atlanta. LGD-4033 exhibited desirable in vivo efficacy on skeletal muscle and bone measurements in animal models of male hypogonadism and postmenopausal osteoporosis. [More]

Discovery of Th22 cells may help in developing effective therapies for chronic skin and respiratory diseases

20. November 2009 05:41
The newly discovered Th22 cells are a previously unknown subset of T helper cells. T helper cells are white blood cells that help activate other immune cells when the body is infected by viruses or bacteria. At the same time they help the body to tolerate own tissue and to prevent or curb inflammation. [More]

Posted in: Medical Science News | Medical Condition News

Tags: , , , , , , ,

Ligand Pharmaceuticals receives $2 million in milestone payments from N. V. Organon

19. November 2009 22:41
Ligand Pharmaceuticals Incorporated announced today that it has received $2 million in milestone payments from N. V. Organon, a subsidiary of Merck & Co., Inc., stemming from its research collaboration that is due to expire at the end of December. [More]

Posted in: Business / Finance

Tags: , , , , , , , ,

Growing use of lasers in surgical and ophthalmic applications drives medical lasers market

18. November 2009 04:45
Growing use of lasers in surgical and ophthalmic applications, as well as higher number of cosmetic procedures, continues to drive the medical lasers market. Prospects for laser application in cosmetic skin resurfacing appear all the more brighter with growing desire for 'preservation of youth' among the baby boomer generation. [More]

Posted in: Device / Technology News

Tags: ,

Melanoma Institute director to present Phase 2 study data of PV-10 for metastatic melanoma

17. November 2009 08:04
Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, announced today that Professor John F. Thompson, MD, Professor of Melanoma and Surgical Oncology at the University of Sydney, Director of the Melanoma Institute Australia, and Lead Investigator of the Phase 2 study of PV-10 for Metastatic Melanoma, will be presenting data at the 3rd World Meeting of Interdisciplinary Melanoma/Skin Cancer Centers on November 21, 2009 in Berlin, Germany. [More]

Th22 cell to control inflammation in body to help fight off infection discovered

17. November 2009 06:19
A new type of immune cell that can be out of control in certain chronic inflammatory diseases, worsening the symptoms of conditions like psoriasis and asthma, is described for the first time this week in the Journal of Clinical Investigation. [More]

Posted in: Medical Science News

Tags: , , , , , ,

PsoriasisDX to present seminar on Genetic Screening for Psoriatic Arthritis

17. November 2009 04:14
A seminar on Genetic Screening for Psoriatic Arthritis will be presented on Tuesday, December 8 from 12-1 PM Pacific Standard Time, hosted by pharmacogenomics research and development innovators PsoriasisDX, pioneers of the world’s first genetic test for psoriatic arthritis (PsA). The seminar will feature leading experts Dr. John Koo and Dr. Wilson Liao. [More]

PhotoMedex to host free seminar to fight against psoriasis with XTRAC Excimer Lasers

16. November 2009 07:15
PhotoMedex, Inc. a leading provider of advanced dermatology, clinical skincare and medical laser products, is hosting a free seminar in Indianapolis, IN on November 17, 2009. [More]

Stelara, first IL inhibitor, expected to change dermatologists’ prescribing habits and alter patient flow models

12. November 2009 04:31
Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that Centocor Ortho Biotech's Stelara, the first interleukin (IL)-12/23 inhibitor to enter the psoriasis drug market in the U.S., is expected to change the prescribing habits of dermatologists and substantially alter patient flow to currently marketed biologic agents, including Amgen's Enbrel and Abbott's Humira. [More]

Posted in: Pharmaceutical News

Tags:

Future trends in the injectable drug delivery market

11. November 2009 03:21
As competition in the pharmaceutical marketplace grows, companies are increasingly looking towards the drug delivery industry to maximize revenues and combat generic competitors. The search for more efficient drug delivery systems is also being driven by the rise in patient demand, healthcare and pharma cost containment, as much as by medical and technological advances. [More]

Lerner Medical Devices selects QuantumMethod for branding and launching its Levia phototherapy device

11. November 2009 03:05
QuantumMethod announced today that Lerner Medical Devices, Inc. has selected the firm as agency of record, tasked with branding and launching Levia®, the company's new Personal Targeted Phototherapy™ device for the self-treatment of psoriasis. Levia® enables their patients to target their small area and scalp psoriasis with therapeutic ultraviolet light via proprietary delivery systems designed for precise, fast and safe treatment. [More]

Posted in: Business / Finance | Device / Technology News

Tags: ,

Levulan PDT may reduce the rate of recurrence of SCCs in solid organ transplant recipients: Study

10. November 2009 07:09
The results of an independent investigator study just published in the online version of Dermatologic Surgery demonstrate that Levulan(®) Photodynamic Therapy (PDT) may reduce the rate of recurrence of squamous cell carcinomas (SCCs) in solid organ transplant recipients (SOTRs), a population with a high incidence of nonmelanoma skin cancer. [More]

Alliance Québécoise du Psoriasis provides information concerning H1N1 vaccination campaign

6. November 2009 02:15
The Alliance Québécoise du Psoriasis (Quebec psoriasis alliance) would like to give its members and other psoriasis sufferers information concerning the massive H1N1 vaccination campaign. [More]

Posted in: Disease/Infection News | Pharmaceutical News

Tags: , , , , ,

Pfizer extends JAK3 research collaboration with Ligand Pharmaceuticals

6. November 2009 01:08
Ligand Pharmaceuticals Incorporated announced today that its research collaboration with Pfizer for JAK3 has been extended by one year. The Research and License Agreement entered into in December 2006 with Wyeth provided for an initial three year research term. Under this extension, Ligand will receive $3.1 million in research payments to continue conducting drug discovery and lead candidate optimization. [More]

Posted in: Pharmaceutical News

Tags: , , , , , , , , ,

Bursting common myths about psoriasis

5. November 2009 01:40
Psoriasis is a real disability that affects approximately one million Canadians. A recent Canadian survey found that the causes and effects of this chronic, recurrent skin disorder are often misunderstood - and the result of these misperceptions can leave a lasting negative impact on those who suffer from this debilitating immune system disease. [More]
News-Medical.Net provides this medical information service in accordance with these terms and conditions. Please note that medical information found on this website is designed to support, not to replace the relationship between patient and physician/doctor and the medical advice they may provide.